Status:
COMPLETED
Genetic Determinants of Amitriptyline Efficiency for Pain Treatment
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsors:
University of Washington
Ludwig-Maximilians - University of Munich
Conditions:
Chronic Pain
Eligibility:
MALE
18-65 years
Phase:
PHASE4
Brief Summary
Low dose tricyclic antidepressant drugs are routinely administered co-analgesics in pain medicine. Amitriptyline is largely considered as a gold standard. Amitriptyline underlies cytochrome CYP2D6 and...
Detailed Description
Background Pain is defined as an ongoing unpleasant sensory experience, which can be classified according to three major, although overlapping, etiologies: nociceptive, inflammatory and neuropathic p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy
- Male
- \>7 Metabolic Equivalents
- Written informed consent
- Exclusion Criteria
- Chronic pain syndrome
- Drug abuse
- Alcohol abuse
- Suspicion of neurologic dysfunction at tested sites
- Ongoing treatment with antidepressants
- Ongoing treatment with analgesics
- Pretreatment with any CYP3A inducers or inhibitors
- Known allergy to tested drugs
- Elevated eye pressure
- Obstructive uropathy
- Heart disease
- Pulmonary disease
- Neurological disease
- Psychiatric illness
Exclusion
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2019
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT02256943
Start Date
November 1 2014
End Date
January 1 2019
Last Update
January 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dep. of Anesthesiology, Bern University Hospital
Bern, Switzerland, 3010